What Are Antibody-drug Conjugates?
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how...
Cancer Research CatalystThe Official Blog of the American Association for Cancer Research
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how...
After surviving brain cancer, former competitive cyclist Chris Baccash dedicated his life to helping others. Baccash now uses his...
At the AACR Special Conference on Advances in Malignant Lymphoma, Ronald Levy, MD, FAACR, of Stanford University, discussed how...
During the second quarter of 2026, oncology approvals issued by the U.S. Food and Drug Administration expanded the treatment...
The June edition of Editors’ Picks from the AACR journals included studies on targeting neural cross-talk to stop glioblastoma...
At the AACR Annual Meeting 2026, a session highlighted progress from four Cancer Grand Challenges teams on the interplay...
The AACR Cancer Disparities Progress Report 2026 included an examination of the growing gap in cancer care between rural...
The cochairs of the AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers—Andrew Futreal, PhD, FAACR,...
Can AI agents do cancer research? Many AI-centric research teams currently believe that with the right training, AI agents...
Chenia Lloyd-Gascho, who was diagnosed with Li-Fraumeni syndrome when he was 8 years old, shared what it is like...
Melanoma expert Ashani T. Weeraratna, PhD, of Johns Hopkins Bloomberg School of Public Health, explains how bemotrizinol—the first new...